Drug Profile


Alternative Names: AZD3293; BACE inhibitor - AstraZeneca; Beta secretase inhibitor - AstraZeneca; LY 3314814

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator Astex Pharmaceuticals; AstraZeneca
  • Developer AstraZeneca; Eli Lilly
  • Class Antidementias; Imidazoles; Pyridines; Small molecules; Spiro compounds
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Alzheimer's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 11 Jan 2017 Eli Lilly and AstraZeneca plan a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT03019549)
  • 21 Nov 2016 Eli Lilly and AstraZeneca plan an extension phase III trial for Alzheimer's Disease in USA, United Kingdom, Australia, Belgium, Canada, France, Germany, Hungary, Italy, Japan, South Korea, Poland, Romania and Spain (PO) (NCT02972658)
  • 22 Aug 2016 AZD 3293 receives Fast Track designation for Alzheimer's disease [PO,Tablet] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top